Media Availability: NIH Grantees Sharpen Understanding of Antibodies that May Cut Risk of HIV Infection

Media Availability: NIH Grantees Sharpen Understanding of Antibodies that May Cut Risk of HIV Infection

Leading Research to Understand, Treat, and Prevent Infectious, Immunologic, and Allergic Diseases           Visit us on the Web NIAID Grantees Sharpen Understanding of Antibodies that May Cut Risk of HIV Infection What immune response should a vaccine elicit to prevent HIV infection? Two studies published this week bring scientists closer to answering this question by identifying previously unrecognized attributes of antibodies that appear to have reduced the risk of HIV infection in the RV144 vaccine clinical trial. Information from these studies and other ongoing research will help scientists refine their efforts to design and test HIV vaccines that build on the success of RV144. Learn more about the new studies.